PD-L1 expression and tumor mutational burden are independent biomarkers in most cancers

PD-L1 expression and tumor mutational burden (TMB) have emerged as important biomarkers of response to immune checkpoint inhibitor (ICI) therapy. These biomarkers have each succeeded and failed in predicting responders for different cancer types. We sought to describe the PD-L1 expression landscape...

Celý popis

Podrobná bibliografia

Vydané v:	JCI insight Ročník 4; číslo 6
Hlavní autori:	Yarchoan, Mark, Albacker, Lee A., Hopkins, Alexander C., Montesion, Meagan, Murugesan, Karthikeyan, Vithayathil, Teena T., Zaidi, Neeha, Azad, Nilofer S., Laheru, Daniel A., Frampton, Garrett M., Jaffee, Elizabeth M.
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	United States American Society for Clinical Investigation 21.03.2019
Predmet:	Clinical Medicine Genetics Immunology Immunotherapy Cancer
ISSN:	2379-3708, 2379-3708
On-line prístup:	Získať plný text
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!